Proto-Oncogene Mas

A protein that is encoded by the MAS1 gene. It is a receptor for ANGIOTENSIN 1-7 and acts as an antagonist of ANGIOTENSIN-2 TYPE 1 RECEPTOR.

Also Known As:

C Mas Protein; C-Mas-1, Proto-Oncogene Proteins; Cellular II-Proto-Oncogene Proteins; II Proto Oncogene Proteins, Cellular; Mas, Proto-Oncogene; Protein Mas, Proto-Oncogene; Protein, C-Mas; Protein, Mas; Protein, Mas1; Proteins, Cellular II-Proto-Oncogene; Proto Oncogene Mas; Proto Oncogene Proteins C Mas 1; C-Mas Protein; II-Proto-Oncogene Proteins, Cellular; Mas Protein; Mas1 Protein; Proto-Oncogene Protein Mas; Proto-Oncogene Proteins C-Mas-1

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Franco, Rafael: 1 article (01/2020)
2.	Labandeira-García, José L: 1 article (01/2020)
3.	Navarro, Gemma: 1 article (01/2020)
4.	Rivas-Santisteban, Rafael: 1 article (01/2020)
5.	Rodríguez-Pérez, Ana I: 1 article (01/2020)
6.	Serrano-Marín, Joan: 1 article (01/2020)
7.	Andrades, Michael E: 1 article (01/2019)
8.	Biolo, Andreia: 1 article (01/2019)
9.	Caetano, Daniel Sturza Lucas: 1 article (01/2019)
10.	Clausell, Nadine: 1 article (01/2019)

Related Diseases

1.	Ventricular Remodeling 11/01/2023 - "The results of this research are as follows: (1) PDZK1 interacts with the carboxyl terminus of Mas through its PDZ1 domain; (2) the expression of PDZK1 and Mas is decreased in rats undergoing hypertensive ventricular remodeling, and PDZK1 upregulation can ameliorate hypertensive myocardial fibrosis and myocardial hypertrophy; (3) PDZK1 enhances the stability of Mas protein through the proteasome pathway, and the proteasome inhibitor MG132 promotes hypertensive ventricular remodeling. "
2.	Inflammation (Inflammations) 01/01/2020 - "SARS-CoV-2 may modulate macrophage-mediated inflammation events by altering the balance between angiotensin II, which activates angiotensin receptor types 1 and 2, and angiotensin 1-7 and alamandine, which activate MAS proto-oncogene and MAS-related D receptors, respectively. "
3.	Hypertrophy 11/01/2023 - "The results of this research are as follows: (1) PDZK1 interacts with the carboxyl terminus of Mas through its PDZ1 domain; (2) the expression of PDZK1 and Mas is decreased in rats undergoing hypertensive ventricular remodeling, and PDZK1 upregulation can ameliorate hypertensive myocardial fibrosis and myocardial hypertrophy; (3) PDZK1 enhances the stability of Mas protein through the proteasome pathway, and the proteasome inhibitor MG132 promotes hypertensive ventricular remodeling. "
4.	Hypertension (High Blood Pressure) 09/01/2015 - "Early aliskiren therapy prevents CR-induced hypertension via ADMA reduction, decreases angiotensinogen expression, and increases renal angiotensin II type 2 receptor and Mas protein."
5.	Cardiomegaly (Heart Hypertrophy) 01/01/2019 - "Exercise promotes physiological cardiac hypertrophy and activates the renin-angiotensin system (RAS), which plays an important role in cardiac physiology, both through the classical axis [angiotensin II type 1 receptor (AT1R) activated by angiotensin II (ANG II)] and the alternative axis [proto-oncogene Mas receptor (MASR) activated by angiotensin-(1-7)]. "

Related Drugs and Biologics

1.	Angiotensin II
2.	angiotensin I (1-7)
3.	Proteasome Inhibitors
4.	Proteasome Endopeptidase Complex (Proteasome)
5.	Type 1 Angiotensin Receptor
6.	Type 2 Angiotensin Receptor
7.	Angiotensin Receptors (Angiotensin II Receptor)
8.	Angiotensinogen
9.	alamandine
10.	aliskiren

Related Therapies and Procedures

1.	Therapeutics